Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Growth in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 4,975 shares, a growth of 895.0% from the November 30th total of 500 shares. Based on an average trading volume of 419,828 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 419,828 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Price Performance

Shares of OTCMKTS PVCT opened at $0.06 on Friday. Provectus Biopharmaceuticals has a 52-week low of $0.05 and a 52-week high of $0.12. The business has a fifty day moving average of $0.07 and a two-hundred day moving average of $0.07.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.